In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NanoString's Series D round brings in $20mm

Executive Summary

Molecular diagnostics company NanoString Technologies Inc. raised $20mm through its Series D round. New investors GE Healthymagination Fund (managed by GE Healthcare and GE Capital), BioMed Ventures, and former Genzyme CEO Henri Termeer were joined by returning backers Clarus Ventures, Draper Fisher Jurvetson, and OVP Venture Partners. Some of the proceeds will be used to advance development of NanoString's first molecular test, a PAM50 gene expression assay for breast cancer.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies